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HaemophiliaThe pathogen safety of blood/plasma-derived products has historically been a subject of signiﬁcant concern to
the medical community. Measures such as donor selection and blood screening have contributed to increase
the safety of these products, but pathogen transmission does still occur. Reasons for this include lack of sensitiv-
ity/speciﬁcity of current screeningmethods, lack of reliable screening tests for some pathogens (e.g. prions) and
the fact that many potentially harmful infectious agents are not routinely screened for. Methods for the puriﬁca-
tion/inactivation of blood/plasma-derived products have been developed in order to further reduce the residual
risk, but low concentrations of pathogens do not necessarily imply a low level of risk for the patient and so the
overall challenge of minimising risk remains. This review aims to discuss the variable level of pathogenic risk
and describes the current screening methods used to prevent/detect the presence of pathogens in blood/
plasma-derived products.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acute bleeding episodes can arise either because of inherited bleed-
ing disorders (e.g. haemophilia, vonWillebrand disease), acquired deﬁ-
ciency of haemostatic components (e.g. due to infection, malignancy or
autoimmune disease), trauma, surgery or as a result of infectionwith an
organism that causes haemorrhagic disease (e.g. Ebola or Marburg
virus) [1]. Various treatment options exist for preventing or treating
acute bleeding episodes, including fresh-frozen plasma/cryoprecipitate,
platelets and plasma-derived/recombinant clotting factor concentrates
[2,3]. The use of blood-derived and recombinant haemostatic products
has increased markedly over recent years, as exempliﬁed by the global
use of factor VIII products (Fig. 1) [4]. This increased use has been driven
by improved availability of clotting factors, increased life expectancy of
people with bleeding disorders [5,6], increased use of prophylaxis for
severe bleeding disorders [7,8] and decreased risk of transmission of in-
fectious agents.
Historically, the risk of transmission of infectious agents via blood/
plasma-derived products has been of great concern to the medical39 081 5466152.
. This is an open access article undercommunity. This risk has reduced dramatically since the implementa-
tion of stricter donation screening/donor selection procedures and im-
proved puriﬁcation procedures, but cannot be fully eradicated.
Furthermore, the implementation of pathogen inactivation technology
for blood/plasma-derived products has further reduced the risk of trans-
mission of both known and emerging pathogens, although results can
be variable according to the methods used [9,10]. However, it is impor-
tant to note that patient risk is highly dependent on the circumstances
underwhich blood products are collected, handled and used. In general,
clinicians assess the level of risk associated with the use of blood/
plasma-derived products by evaluating factors such as patient charac-
teristics (e.g. age, immune status, geographical location, lifestyle) and
the nature of the pathogen (e.g. physical characteristics, level of viru-
lence, chronicity of infection, prevalence). The presence of a particular
pathogen within blood/plasma-derived products may pose a signiﬁcant
threat to speciﬁc patient groups (e.g. the elderly or immunocompro-
mised), while being of low risk to the general population (e.g. HEV).
While the clinical assessment of risk is based on a variety of factors,
the virological assessment of risk is based solely on the presence or ab-
sence of pathogens. The presence of pathogens implies the possibility of
infection, so only pathogen-free products can be described as entirely
risk-free. Adopting the virological approach (i.e. discarding all productsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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pathogen transmission, but may result in the unnecessary wastage of
blood/plasma-derived products.
Since recombinant clotting factors are not derived from blood or
plasma, they present a minimal risk of pathogen transmission (particu-
larly third generation factors, which have no contact with blood/
plasma-derived components whatsoever) and can therefore be consid-
ered safer than using plasma-derived clotting factor concentrates [11].
However, there has been concern that the use of recombinant clotting
factors may be associated with an increased rate of inhibitor formation
in patients who regularly receive these products [12]; this is another
factor that may inﬂuence the overall clinical assessment of patient risk.
Recombinant clotting factors are available for the treatment of
haemophilia A (FVIII) and B (FIX) and factor VII/XIII deﬁciency, while
plasma-derived concentrates are available for most other clotting fac-
tors (including vonWillebrand factor, ﬁbrinogen and the vitamin K de-
pendent clotting factors). In some cases only fresh frozen plasma and
cryoprecipitate are available for replacement therapy (e.g. factor V deﬁ-
ciency). Ideally, plasma and plasma-derived products would be
completely replaced by recombinant products in order to minimise
the risk of pathogen transmission; however, this is not always possible.
A recent article comprehensively reviewed the pathogen safety of
plasma-derived and recombinant clotting factors [13].
This review examines the potential for transmission of infectious
agents that might be present in blood/plasma-derived products used
to treat haemostatic disorders. We focus on the identities of these
agents and the screening procedures used for their detection, as well
as the limitations of screening. Current unmet needs in the ﬁeld of path-
ogen safety of blood/plasma-derived products are also discussed.
2. Methodology
The PubMed database was interrogated from 1 January 2000 to the
present using the search strings ‘bleeding disorders OR haemophilia’Fig. 1. Use of plasma-derived and recombinant factor VIII products in selected countries.
Results are from Stonebraker et al. (1996–2006) [4] and WFH Annual Global Surveys
(2007–2012) [196].and ‘pathogens AND blood safety’. The search terms ‘virus’, ‘bacteria’,
‘haemorrhagic disorders’, ‘von Willebrand disease’, ‘FVII deﬁciency’
and ‘FXIII deﬁciency’were added to this search but did not yield any ad-
ditional pertinent result. The bibliographies of reviewswere also used to
identify relevant references and individual searches were conducted for
information on speciﬁc pathogens. Information and opinions were also
provided by the authors.
3. Infectious agents present in blood/plasma-derived products:
lessons from the past and current concerns
A large number of pathogenic agents (including viruses, protozoan
parasites and prions) can be transmitted via blood/plasma-derived
products and are capable of causing disease in humans (Table 1). The
presence of viruses in plasma-derived products became a concern in
the 1980s, when 60–70% of patients with severe haemophilia became
infected with human immunodeﬁciency virus (HIV-1) [6]. This concern
continued with the discovery that 80% of patients treated with plasma-
derived products prior to 1992 had become infected with hepatitis C
virus (HCV) [5]. Current donor selection and screening practices have
improved our ability to detect or reduce the presence of pathogens in
blood/plasma-derived products; for example, the residual risk of
transfusion-transmitted infection (TTI) with HIV/HBV/HCV has fallen
to near or less than 1 per million transfused units [14,15]. Despite this
success, however, a residual risk still remains.
3.1. Potential risk
The pathogenic agents shown in Table 1 (and the Supplementary
Appendix) do not form an exhaustive list. Many microorganisms that
are normally non-pathogenic have the potential to cause disease
when responding to changes in the biological environment, or when
transfused to an immunosuppressed patient. In addition, there is still a
risk that new and emerging pathogens may enter the blood supply
(Table 2).
4. Screening for pathogens
The standard assays commonly used for blood screening are nucleic
acid ampliﬁcation technology (NAT) and immunoassays for detection of
antibody and/or antigen. Immunoassays are frequently used for screen-
ing purposes as multiple samples can be processed together and they
may yield semi-quantitative results. NAT assays allow earlier pathogen
detection than with immunoassays, but they are also more costly and
complex. Assay selection is generally determined by the level of accura-
cy/speed required, but factors such as the resources available (e.g. staff,
infrastructure), assay complexity and cost considerations (e.g. consum-
ables) must also be considered. Most assays for blood donation screen-
ing are mandatory (particularly in Europe and North America) and the
World Health Organization (WHO) recommends that all whole blood
(and blood which has been processed by apheresis) should undergo
pathogen screening before it is used for clinical or manufacturing pur-
poses. Screening for HIV-1, HIV-2, HBV, HCV and Treponema pallidum
subspecies pallidum (T. pallidum; the causative agent of syphilis) is
strongly advised. The WHO and World Federation of Hemophilia
(WFH) suggest that countries should carry out individual routine
screening for further pathogens based on epidemiological information
for their region e.g. HTLV-1 and Trypanosoma cruzi [16]. The WFH also
acknowledges the positive impact of HIV, HBV and HCV screening on
global blood safety and recommends that these screening tests be im-
plementedwhenever possible [2]. Details of the serological tests carried
out on individual donor plasma and NAT testing of plasma mini-pools
are shown in Tables 3 and 4 [17].
It is recommended that theminimum evaluated sensitivity/speciﬁc-
ity level of any assay used for blood donation screening should be 99.5%
or higher [16]. However, not all assays fulﬁl these criteria as sensitivity/
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organism being tested for (see Table 1 for details). Therefore, the gener-
al advice is to screen donated blood to as high a standard as possible
[16].
4.1. Blood donation screening: assays for key pathogens
4.1.1. HIV, HBV and HCV testing
In the early stages of infection with HIV, HBV or HCV, viraemia oc-
curs in the host's bloodstream at variable levels. Viral antigens may ap-
pear at the same time as DNA/RNA, but more often become detectable
several weeks later. Speciﬁc antibodies are measurable 2 to 6 weeks
after infection; the time between initial infection and the appearance
of detectable parameters of infection (e.g. viral nucleic acid/antigens/
antibodies) is known as the ‘window period’ [18–20].
4.1.1.1. HIV.When screening blood for the presence of HIV-1/HIV-2, the
use of a combined antigen/antibody assay is advised (combinedHIV p24
Ag and anti-HIV-1 + anti-HIV-2 antibodies) as it allows earlier detec-
tion of infection. The performance of NAT testing is mandatory in
many countries and further reduces the window period (from around
20 to 11 days) [20–22].
4.1.1.2. HBV. The majority of diagnostic laboratories focus on the detec-
tion of HBsAg, which is the ﬁrst detectable serological marker of infec-
tion. However, there is a risk that the HBsAg concentration may
decline to undetectable levels during the course of infection, yielding a
false negative result [23]. Screening for antibodies to HBc is the most
conservative approach for identifying potentially exposed donors, as
this identiﬁes all individuals who have ever immunologically experi-
enced any type of HBV infection (either current, chronic or resolved)
andwhomay experience viral reactivation during their lifetime (partic-
ularly under conditions of immunosuppression). However, assays to
measure HBc antibodies are relatively non-speciﬁc and do not always
correlate with the presence of HBV virus in plasma [18]. Also, we cannot
exclude the possibility that donorswho test positive for anti-HBc do not
have pulsed recurrences of virus replication, resulting in the presence of
low levels of HBV-DNA in plasma. For these reasons, national transfu-
sion services do not always routinely screen donations for anti-HBc.
NAT assays can be carried out, but their use is restricted by potentially
low levels of viral DNA [16,18]. The combined use of HBsAg screening
tests and NAT assays has reduced the window period for detection of
HBV infection from approximately 60 to 35.5 days [20,24]. Mutant
HBV strains (escape variants) should also be considered, as theymayoc-
casionally escape serological detection (although most can be detected
by NAT assays) [24,25]. These HBV-variants are rare, but therefore
more likely to enter and contaminate the blood supply as they are
more difﬁcult to detect [25]. In summary, the screening of blood sup-
plies for the presence of HBV is effective, but an optimal screening sys-
tem has not yet been deﬁned.
4.1.1.3. HCV.HCV (both recent and chronic infection) can be detected by
screening blood for the presence of both HCV antigen andHCV antibody
(anti-HCV). Seroconversion occurs at approximately 6–8 weeks post-
infection; however, steady improvements in screening technology (in-
cluding the adoption of NAT assays) have reduced the window period
to approximately 1–3 weeks [20,26]. As with HIV, NAT assays are
more useful for detecting early infection, although the issue of low
viral RNA concentration persists [27,28].
4.1.2. HTLV-1 testing
HTLV-1 and HTLV-2 are endemic in some regions, but very rare in
others, and therefore screenings are conducted on a geographical or
at-risk basis. The presence of virus is mostly inferred by the detection
of virus-speciﬁc antibodies, using sensitive immunoassays [16].4.1.3. Syphilis testing
In this instance, screening involves detection of non-speciﬁc, non-
treponemal or speciﬁc treponemal antibodies. NAT assays are generally
not used [29]. Speciﬁc antibody tests identify all individuals who have
ever been exposed to this bacterium (andmay continue to yield positive
results for more than ten years following initial infection), while the
non-speciﬁc tests (e.g. VDRL or cardiolipin tests) are primarily of use
in identifying donors who may have an active infection. Since
T. pallidum is heat-sensitive and cannot readily withstand extended
storage at low temperatures, storage at 4 °C for more than three days
is sufﬁcient to render the pathogen non-infectious. However, blood
components (e.g. platelets) that are stored at temperatures of around
20 °C do present a risk of T. pallidum persistence. Therefore screening
for antibodies of this organism is recommended [16].
4.2. Testing for emerging viral pathogens
4.2.1. West Nile virus
Blood can be screened for further pathogens as appropriate, accord-
ing to geographical location, seasonal activity of the vector and also pa-
tient risk factors. A current viral pathogen of interest is the mosquito-
borne ﬂavivirus West Nile virus (WNV), which was conﬁrmed to have
been transmitted via transfusion in 2002 [30]. An immediate screening
policy was put in place in the USA in order to reduce the risk of further
transmission. This policy included deferral of any individual displaying
symptoms of infection, quarantine of plasma collected during periods
of high mosquito activity (when WNV is most prevalent) and the
rapid development/use of WNV-speciﬁc NAT and serological assays.
Thesemeasureswere highly effective and caused a signiﬁcant reduction
in the number of conﬁrmed cases ofWNV transfusion-related transmis-
sion. However, WNV outbreaks still occur within the Americas, indicat-
ing a potential need for seasonal blood screening for WNV [31]. WNV
outbreaks have also occurred in Europe (including Italy and Greece),
prompting the implementation of seasonal blood screening procedures
in the affected regions of those countries [32].
4.2.2. Chikungunya virus
This is anothermosquito-bornepathogen that could potentially pose
a risk to transfusion safety, although to date reports of transfusion-
related transmission of this virus are rare [33]. A mutated form of the
Chikungunya virus has been responsible for several epidemics in the
past decade, spreading to the Reunion Islands in the Indian Ocean
(2005), Italy (2007) and the Caribbean area (2012/2013) [34–36]. The
virusmay bedetected in blood donors byNAT,whichwill help to reduce
the level of transmission risk [35].
4.2.3. Parvovirus B19
There is also concern about the possibility of parvovirus B19 in the
blood supply. B19 is prevalent worldwide, with seroprevalence in
blood donors varying from between 0.2–1.3% in the USA, Europe and
Africa and 25–40% in Asia [37]. The risk of parvovirus transmission is
higher when units of blood are pooled (e.g. to create batches of clotting
factor concentrates, albumin etc.) and so individuals with bleeding dis-
orders are at a higher risk of infection. B19 DNA was detected in 26% of
clotting factor concentrates in a recent German study [38], and another
study found that populations receiving blood-derivedproductswere 1.7
times more likely to display antibodies to B19 than populations who
had not received blood products [39]. B19 lacks a lipid envelope,
which renders it highly resistant to somemethods of pathogen inactiva-
tion [40]. Screening of blood donations for B19DNA is not currently rou-
tine, but many manufacturers only process plasma that has been
screened for the absence of B19 DNA in order to reduce the risk of trans-
mission [41]. Given the prevalence of B19 in different populations, it is
difﬁcult to deﬁne the residual TTI risk of this virus. However, it is clear
that a transmission risk does exist.
Table 1
Blood-transmissible pathogens.
Transmissible
agent
Geographic
distribution
(% of global
population
infected)
Testing procedure Detection level in
general clinical use
Minimum detection
level possible
(in development)
Testing sensitivity Testing speciﬁcity
Prions
vCJD Rare [94] Solid state binding
matrix/immuno-assay
[55,95]
N/A N/A ≥71% [55,95] ≥98% [55,95]
Viruses
Chikungunya virus Widespread
(prevalent in
Africa, Asia
and Latin--
America) [96]
Antibody/NAT [96] NAT: 40–350
copies/ml [97]
NAT: 10–100 copies/ml
[98]
Antibody: varies
according to disease stage
and test type.
Immuno-chromatographic
test: 1.9–3.9% (acute
infection)
ELISA: 3.9% (acute), 84.1%
(convalescent)
NAT: RT-PCR — 88.5%
(acute) [99]
Antibody: varies
according to disease stage
and test type.
Immuno-chromatographic
test: 92.5–95.0%
(acute infection)
ELISA: 92.5% (acute),
91.0% (convalescent)
NAT: RT-PCR — 100%
(acute) [99]
Cytomegalovirus
(CMV)
Widespread
[69]
Antigen/NAT NAT: 446 copies/ml
(whole blood) [100]
139 copies/ml
(NAT; qPCR) [101]
Not available Not available
Dengue virus Widespread;
50% of global
population at
risk [102]
Antibody/NAT NAT: 160–600
copies/ml (DENV-1, 3
and 4)
2000–6000
copies/ml (DENV-2)
[103] based on 1 PFU
= 1000–3000 RNA
copies [104]
N/A: current main
research focus is on
developing
serotype-speciﬁc tests
Antibody: 96–98% (IgM)
[105]
NAT: High for DENV-1, 3
and 4; lower for DENV-2
[103]
Antibody: 78–91% (IgM)
[105]
NAT: 100% [103]
Hepatitis B virus
(HBV)
Widespread;
29% infected,
5% chronically
infected [106]
Antibody/NAT NAT: Reliable (≥99%
detection) from 84
copies/ml [107]
based on 1 IU/ml =
5.6 copies/ml [108]
NAT: 42–52 copies/ml
(Ultrio); 4–10 copies/ml
(Ampliscreen/UltraQual)
[58]
Antibody: ≥90% (anti-HBc
assay), 98% (anti-HBsAg
assay) [109]
NAT: 99.3% (Procleix
Ultrio) [107]
Antibody: ≥78.9 (anti-HBc
assay), up to 100%
(anti-HBsAg assay) [109]
NAT: 99.8% (Procleix
Ultrio) [107]
Hepatitis C virus
(HCV)
Widespread;
3% [110]
Antibody/NAT NAT: 17 copies/ml
(4-reaction kit
format), 1664
copies/ml (primary
pool format), 8806
copies/ml (master
pool format), based
on 1 IU/ml = 2.5
copies/ml [111,112]
NAT: 6.1 copies/ml
(50% detection point,
individual samples)
Antibody: 99%
(anti-HCV-cAg) [113,114]
NAT: 70.7–90.2% [111],
99.9% (Procleix Ultrio)
[107]
Antibody: 99.2%
(anti-HCV-cAg) [113,114]
NAT: High [111], 98.1%
(Procleix Ultrio) [107]
Hepatitis E virus
(HEV)
Widespread
[115]
Antibody/NAT NAT: 5.9–114
copies/ml (MP-NAT),
47.3–226 copies/ml
(ID-NAT) [116] based
on 1 IU/ml = 1.25
copies/ml [117]
NAT: ≥5.8 copies/ml
[118] based on 1 IU/ml
= 1.25 copies/ml [117]
Antibody: 72-98% [119]
NAT: High. Varies from 5.9
copies/ml (Real-Star HEV
RT-PCR) to 114 copies/ml
(Ceeram) for MP-NAT and
from 47.3 copies/ml
(Real-Star HEV RT-PCR )
to 226 copies/ml
(ampliCube HEV RT-PCR)
for ID-NAT [116]
Antibody: 78-96% [119]
NAT: High [116]
Human
Herpesvirus-8
(KSHV)
Widespread,
with variable
prevalence
(≤5–50%);
endemic in
sub-Saharan
Africa, parts of
Asia and Ocea-
nia [120]
Antibody/NAT NAT: 63 copies/ml
(Viracor IBT) [121]
N/A Antibody: 65-100% [122]
NAT: High (63 copies/ml)
[121]
Antibody: 96-99% [122]
NAT: High — no cross
reactivity detected against
adenoviruses, BKV, CMV,
EBV, HSV-1, HSV-2, HHV-6
variant A, HHV-6 variant
B, HHV-7, JCV, parvovirus
B19, SV-40 or VZV. [121]
Human
immunodeﬁciency
virus
(HIV-1 and HIV-2)
Worldwide
(0.5%);
endemic in
sub-Saharan
Africa (5%)
[123]
Antibody/NAT NAT: 20-50
copies/ml [124]
N/A Antibody: ≥99.9% [125]
NAT: 99.9% (Procleix
Ultrio) [107]
Antibody: 99.5–99.9%
[125]
NAT: 99.8% (Procleix
Ultrio) [107]
Human
T-lymphotropic
virus 1 and 2
(HTLV-1/2)
HTLV-1:
Endemic in
Japan, Africa,
South America
and Caribbean
Antibody/NAT Not speciﬁed:
antibody detection
kits routinely used
[127,128]
NAT: HTLV-1–1.2
copies/reaction (i.e.
12–48 copies/ml, based
on a reaction volume of
10–50 μl); HTLV-2–19
Antibody: 100% [130]
NAT: 99.4% (HTLV-1 and
2) [131]
Antibody: ≥99.4% [130]
NAT: 98.5% (HTLV-1 and
2) [131]
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Table 1 (continued)
Transmissible
agent
Geographic
distribution
(% of global
population
infected)
Testing procedure Detection level in
general clinical use
Minimum detection
level possible
(in development)
Testing sensitivity Testing speciﬁcity
HTLV-2: Prev-
alent in
Central/West
Africa, the
Americas and
Europe [126]
copies/reaction (i.e.
76–191 copies/ml, based
on a reaction volume of
10–50 μl) [129]
Parvovirus B-19 Widespread,
variable
prevalence
(0.2–40% in
European and
Asian blood
donors) [37]
Antibody/NAT NAT: 668 copies/ml
(based on 1 IU/ml =
3.34 copies/ml)
[132,133]
NAT: 10 copies/reaction
(i.e. 100–500 copies/ml,
based on a reaction
volume of 10–50 μl)
[134]
Antibody: 89.1% [135]
NAT: ≥93% [132]
Antibody: 99.4% [135]
NAT: ≥97% [132]
Parvovirus 4 Widespread,
variable
prevalence
(2–35%)
[136–138]
NAT NAT: 200–500
copies/ml [139,140]
NAT: 10 copies/reaction
(i.e. 100–500 copies/ml,
based on a reaction
volume of 10–50 μl)
[134]
Not available Not available
Torque-tenovirus
(TTV)
Present
worldwide at
variable
prevalence
(higher in
developing
countries)
[141]
NAT NAT: no general test
— PCR used to
conﬁrm presence.
NAT: ≥100
copies/reaction (i.e.
1000–5000 copies/ml,
based on a reaction
volume of 10–50 μl)
[142]
NAT: Up to 100% [142] NAT: ≥96% [142]
West Nile virus
(WNV)
Widespread
(Africa, West
Asia, Middle
East, Europe
and North and
South
America) [90]
Antibody/NAT NAT: 100 copies/ml
[143]
NAT: ≥9.8 copies/ml
[144]
Antibody: 50% (IgM), 86%
(IgG) [145]
NAT: High [144]
Antibody: 95% (IgM), 69%
(IgG) [145]
NAT: High [144]
Bacteria
Treponema pallidum
subspecies pallidum
Widespread;
(0.5% of global
population
infected)
[146]
Antibody/NAT/dark ground
microscopy DGM)
NAT: 32,000 copies/ml
[147]
NAT: 82% [148]
Antibody: 78–88%
(primary syphilis), 100%
(secondary), 95–100%
(latent), 71–96 (late)
[149]
DGM: 79–97% [147]
NAT: 95% [148]
Antibody: 96–99%
DGM: 77–100% [147,149]
Yersinia
enterocolitica,
Salmonella enterica,
Listeria
monocytogenes,
Coxiella burnetii
(only during
outbreaks)
Rare, donor
selection
dependent
Not done N/A N/A N/A
Protozoa
Babesia spp Widespread;
predominantly
in United
States and (less
frequently)
Europe [150]
Antibody/NAT Antibody:
10000–100000
parasites/ml (Giemsa
staining) [151]
NAT: 5000–10000
parasites/ml [151]
Antibody: ≥97% [152]
NAT: High [151]
Antibody: ≥97% [152]
NAT: 100% [151]
Leishmania spp Widespread;
1.3 million
new cases per
year [153]
Antibody/NAT NAT: ≥10
parasites/ml (PCR;
sensitivity varies
according to
method) [154]
NAT: ≥10 parasites/ml
[154]
Antibody: 75-95% [155]
NAT: 98.7% (kinetoplast
DNA PCR), 91% (ITS1 PCR),
53.8% (SLME PCR) [156]
Antibody: 70-98% [155]
NAT: 57.1% (kinetoplast
DNA PCR), 100% (ITS1 PCR
and SLME PCR) [156]
Plasmodium spp Widespread
(most
common in
sub-Saharan
Africa). 30% at
risk [157]
Antibody/NAT Microscopy: 50000
parasites/ml [158]
NAT: b10 parasites/ml
[158]
Antibody: ≥95% [159]
NAT: 76.1–100%
[158]
Antibody: ≥97.7% [159]
NAT: 89.6–100%
[158]
Trypanosoma brucei
gambiense/rhodiense
Regional in
Africa, 10% at
risk [160]
Direct microscopic
visualisation/Antibody/NAT
NAT: b100
trypanosomes/ml
[161]
NAT: 1–10
trypanosomes/ml
[162]
Antibody: CATT — 87–98%
[161]
NAT: 88% [163]
Antibody: CATT — 95%
[161]
NAT: 99.2% [163]
(continued on next page)
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Table 1 (continued)
Transmissible
agent
Geographic
distribution
(% of global
population
infected)
Testing procedure Detection level in
general clinical use
Minimum detection
level possible
(in development)
Testing sensitivity Testing speciﬁcity
Trypanosoma cruzi 0.1–0.2%
(mostly Latin
and South
America) [164]
Antibody/NAT NAT: ≥0.5
parasites/ml [165]
NAT: 0.05 parasites/ml
[165]
Antibody:75–100%
(majority N 90%) [166]
NAT: 83.3–94.4% [165]
Antibody: ≥97% [166]
NAT: 85–95% [165]
In cases where no overall ﬁgures are available, speciﬁcity/sensitivity has been described as low, medium or high (as appropriate).
CATT, card agglutination test for Trypanosomiasis; ID-NAT, individual donation NAT; MP-NAT, mini-pool NAT; NAT, nucleic acid testing; PCR, polymerase chain reaction; PFU, plaque-
forming unit.
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The potential presence of hepatitis E virus (HEV) in blood or blood-
derived products is relevant. Currently there seems to be a discrepancy
between the number of HEV-RNA positive blood donations in Europe
(ranging from 1 in 1240 in Germany to 1 in 1761 donations in the
Netherlands) [42], and the low number of conﬁrmed cases of hepatitis
E in blood transfusion recipients (one conﬁrmed case in the UK
[2006], one in France [2007] and two in Germany [2014]) [43–45].
This indicates that the subject of HEV infectivity and pathogenicity
needs to be investigated further [46–49]. There is also a debate over
the necessity of introducing screening blood for the presence of HEV;
the virus is not currently screened for in the UK and other European
countries, although one study of English donors found HEV to be wide-
spread (1 in 2848donations)within thedonor population [50]. Since in-
fection with this virus can be harmful to immunocompromised
individuals, the potential need for introducing HEV screening should
be considered [42].
The residual risk for TTI of HBV, HCV, HIV and HEV in selected coun-
tries is given in Table 5.4.3. Prions
Despite recent advances in methods for the detection of prions, no
single method has been developed as a screening test for blood, al-
though several methods in animal models show great promise
[51–53]. In humans, a protocol for the evaluation of a blood-based test
for its suitability in the diagnosis of variant Creutzfeldt–Jakob disease
(vCJD) has been established, but no test yet appears to satisfy the re-
quirements of sensitivity and speciﬁcity [54]. The only report so far of
a blood-based diagnostic test for vCJD claimed an assay sensitivity of
71.4% and a speciﬁcity of 100% in symptomatic patients and its potential
applicability as a screening test to detect asymptomatic vCJD infection
has recently been investigated [55]. There is currently no strategy for
conﬁrming a positive screening result, although the protein misfolding
cyclical ampliﬁcation technique has recently been shown to yieldTable 2
Emerging blood-transmissible pathogens.
Recently emerging
pathogen
Pathogen
structure/classiﬁcation
Year of
emergence
Mode of transmission
Bas Congo virus Enveloped; rhabdovirus 2009 Direct contact (human
Huaiyangshan
Bunyavirus
Enveloped; bunyavirus 2010 Direct contact (human
Inﬂuenza H5N1 Enveloped; orthomyxovirus 2005 Airborne, direct contac
Inﬂuenza H7N9 Enveloped; orthomyxovirus 2012 Direct contact (zoonot
Lujo virus Enveloped; arenavirus 2008 Airborne, direct contac
Marseillevirusa Marseillevirus 2010 Blood-borne, faecal–or
MERS coronavirus Enveloped; coronavirus 2013 Airborne, direct contac
SARS coronavirus Enveloped; coronavirus 2003 Faecal/oral, airborne, d
NJ polyomavirus Non-enveloped polyomavirus 2014 Direct contact, saliva, b
a Unconﬁrmed— may have been the result of laboratory contamination [184].positive results in buffy coat/white blood cell samples from a small
number of patients with vCJD [56].4.4. Interpretation of test results and practicalities of screening
4.4.1. Assay speciﬁcity and sensitivity
Extensive use of blood donor selection and testing does not always
guarantee a safe product. If the test is insufﬁciently sensitive, then
false negatives may occur. Alternatively, tests which are not sufﬁciently
speciﬁc (e.g. anti-HBc assay for HBV) may cause false positive results,
leading to an unnecessary decrease in the number of clotting products
available [16]. Torque Tenovirus (TTV) is an example where testing
speciﬁcity has been an issue, as this virus exists in various divergent
forms (23 distinct genotypes have been identiﬁed thus far) [57]. Since
TTV is often detected in healthy individuals and is not associated with
any particular disease, routine screening for this virus is not considered
to be necessary; even a test with excellent sensitivity/speciﬁcity would
not contribute to increase the level of safety of blood/plasma-derived
products with regard to TTV.
Insufﬁcient assay sensitivity remains a rare but potential problem
when blood donations are screened during thewindow period of initial
HBV, HCV or HIV infection. An increase in testing sensitivity threshold is
needed to prevent HBV transmission via blood/plasma-derived prod-
ucts and by blood transfusion, as extremely low concentrations of HBV
(e.g. 1.6 copies/ml) is capable of viral transmission (see above section
on anti-HBc positive patients) [58]. In the case of HIV and HCV, even
NAT testing may not always be sufﬁcient to ensure sufﬁciently high
levels of safety as virus transmission has previously occurred after trans-
fusion of blood with undetectable levels of viraemia [59].
Recent reports have highlighted concerns about the inability of NAT
assays to detect different variants of HIV. There have been at least four
cases in which the presence of HIV-1 RNA was undetected by NAT
assay screening, potentially putting transfusion recipients at risk [21].
Two of these false-negative results occurred due to genetic mutation
in the viral RNA regions targeted by NAT assay primers (although inReferences
–human and zoonotic), nosocomial [167]
–human), vector-borne, blood-borne, airborne (potentially) [168,169]
t (human–human and zoonotic) [170–172]
ic and potentially human–human),airborne [172,173]
t (human–human and zoonotic), nosocomial, blood-borne (potentially) [174,175]
al (?) [176,177]
t (human–human and zoonotic), nosocomial [178,179]
irect contact (human–human and zoonotic), nosocomial [180–182]
lood? [183]
Table 3
Summarised table of serologic tests on individual donor plasma (WFH 2012) [17].
Plasma source Serologic tests performed on individual
donor plasmaa,b
US paid apheresis (Talecris, Grifols,
others)
Syphilis, HIV-1/2, HBsAg, HCVAb, ALT
United States, recovered,
unpaid
Syphilis, HIV-1/2, HTLV-1&2, HBcAb,
HBsAg, HCVAb, ALT
Baxter BioScience: United States,
Austria, Germany, Sweden, Czech
Republic, Switzerland, Norway
Syphilis, HIV-1/2, HBsAg, HCVAb
CSL Behring: Austria, Denmark,
Germany, United States
Syphilis (US), HIV-1/2, HBsAg, HCVAb
Biotest: Austria, Belgium, Germany,
United States, Switzerland
HIV-1/2, HBsAg, HCVAb
Intersero: Austria, Belgium,
Germany
Syphilis, HIV-1/2, HBsAg, HCVAb, ALT
Germany unpaid Syphilis, HIV-1/2, HbsAg, HCVAb, ALT
Octapharma: Sweden, Austria,
Germany
Syphilis, HIV-1/2, HBcAb, HBsAg, HBcAb,
HCVAb
American Community Blood Centers,
unpaid (Octapharma)
Syphilis, HIV-1/2, HTLV-1&2, HBcAb =
anti-HBc, HBsAg, HCVAb
Finnish Red Cross BS: Finland, unpaid Syphilis, HIV-1/2, HBsAg, HCVAb.
HTLV-1&2 1st donation.
Sanquin: The Netherlands Syphilis, HIV-1/2, HTLV-1&2, HBsAg,
HBcAb, HCVAb
LFB: France Syphilis, HIV-1/2, HTLV-1&2, HBcAb,
HBsAb, HBsAg, HCVAb
Grifols: Spain, Czech Republic,
Slovakia
Syphilis, HIV-1/2, HBsAg, HCVAb
Kedrion: Italy Syphilis, HIV-1/2, HBsAg, HCVAb, ALT
National Bioproducts Institute:
South Africa
Syphilis, HIV-1/2, HBsAg, HCVAb
Australian Red Cross Blood Service Syphilis, HIV-1/2, HTLV-1&2, HBsAg,
HCVAb
New Zealand Blood Service Syphilis, HIV-1/2, HBsAg, HCVAb.
HTLV-1&2 (1st donation only)
Centre for Transfusion Medicine,
Singapore
Syphilis, HIV-1/2, HBsAg, HCVAb
National Blood Center, Malaysia Syphilis, HIV-1/2, HBsAg, HCVAb
Hong Kong Red Cross BTS Syphilis, HIV-1/2, HTLV-1&2, HBsAb,
HBsAg, HCVAb
Taiwan Blood Services Foundation Syphilis, HIV-1/2, HTLV-1&2, HBsAb,
HBsAg, HCVAb, ALT
Japan Syphilis, HIV-1/2, HTLV-1, HBcAb, HBsAb,
HBsAg, HCVAb, ALT, B-19 parvovirus
Korean Red Cross: South Korea Syphilis, HIV-1/2, p-24 antigen, HBsAg,
HCVAb, ALT
Shanghai RAAS Blood Products Co:
China
Syphilis, HIV-1/2, HBsAg, HCVAb, ALT
Bio Products Laboratory, UK: US paid
apheresis
Syphilis, HIV-1/2, HBsAg, HCVAb.
HTLV-1&2, HBcAb (recovered only)
a Serological targets for HIV detection include p24 antigen and anti-HIV-1/2 antibodies
[185,186].
b Nontreponemal tests are routinely used to screen blood for the presence of Treponema
pallidum subspecies pallidum (T. pallidum, the causative agent of syphilis). These tests
measure both proteins from the Treponema cell surface and IgG/IgM antiphospholipid
antibodieswhich are produced by the host in response to cell damage in the early stages
of infection [150].
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negative results can be avoided by designing NAT assays that target a
minimum of two ampliﬁcation regions; such testing will be mandatory
in Germany from 2015 [21,62]. It is hoped that as the sensitivity and
speciﬁcity of NAT tests continue to improve, cases of undetected infec-
tion may become less of an issue in the future.
4.4.2. The need for multiple methods of screening
A recent report suggests that it is not necessary to carry out serolog-
ical screening for multiple HBV markers, and that NAT based screening
is preferred [58]. However, there is a risk that the practice of relying
upon a single method of screening may lead to a higher incidence of
false-negative results. In one case of transfusion-associated parvovirus
B19 transmission, donated blood was screened for the presence of B19antigen and deemed to be safe since no antigen was detected. Since
the recipient subsequently developed B19 infection, the donation was
re-analysed and found to contain B19 DNA [63]. Reports such as this
support the argument for multiple parameter testing.
The localisation of pathogens within blood may also inﬂuence ease
of detection. For example, WNV is present at 10-fold higher levels in
whole blood than in plasma in viraemic seropositive donors. The situa-
tion is reversed in viraemic seronegative donors, who display higher
WNV levels (4-fold) in plasma than in whole blood [64]. Also, cell-
associated viruses such as CMV and HTLV-1 are less frequently trans-
mitted with the use of leukoreduced products [65,66], indicating that
these viruses are less likely to be found in blood/plasma-derived prod-
ucts. The minimum infective dose (MID: the lowest number of patho-
genic particles required to successfully infect a host) of a particular
pathogen is more likely to be reached in whole blood or blood-derived
components, making the use of plasma-derived or recombinant clotting
factors the safest option.4.4.3. Infective dose
To date, studies attempting to measure human MID values have
generally determined the viral concentration needed to infect a particu-
lar percentage of the exposed population (e.g. 50%). This value (the
human infective dose for 50% of the population) is referred to as HID50
and is often described as the human MID [67]. The HID50 value varies
greatly between pathogens (even if they are physically similar) [68]
and also varies depending upon the immune status of the recipient, as
immunocompromised individuals, neonates and the elderly are at
greater risk of infection than healthy individuals [67].When this ﬁnding
and the prevalence of immunocompromised patients receiving blood
products are both taken into account, it implies a need for screening
tests to have the highest sensitivity possible.4.4.4. Patient characteristics
The impact of transmission onmorbidity andmortality is dependent
on patient characteristics. For example, although the vast majority of
cases of CMV infection are not clinically important, inﬂuencing factors
such as genetic predisposition, malnutrition and pre-existing infection
can lead to the development of severe disease [69]. National screening
programmes do not currently screen for CMV as standard, but NAT as-
says exist and may be carried out if required, e.g. if blood is speciﬁcally
intended for vulnerable recipients, such as pregnant women or trans-
plant patients [70]. It is the opinion of the authors that both serological
assays and NAT tests should be used in order to reach the highest level
of safety possible, particularly when in the case of immunosuppressed
patients.5. Other means of reducing and managing pathogen risk
As well as blood donation testing, a range of other measures are
used to increase the pathogen safety of blood- and plasma-derived
products. These include donor selection and screening, recipient
vaccination and the use of blood product puriﬁcation/inactivation
methods. The choice of inactivation method also impacts upon the
level of risk.5.1. Selection and screening of donors
Questionnaires are often used to attempt to assess donors' health
status and their potential exposure to various risks. Donors can be ac-
cepted or rejected on the basis of these answered questionnaires, or al-
ternatively their bloodmay be put through additional screening tests as
appropriate [16,31].
Table 4
Plasma inventory hold and NAT testing of mini-pools (WFH 2012) [17].
Company or Fractionator Mini-Pool NAT Testsa Manufacturing Pool NAT
Testsb
NAT on Final Productc Inventory
Holdd
Mini-Pool
Sizee
CSL Behring: United States, Germany HAV, HBV, HCV, HIV-1, B-19 parvovirus HAV, HBV, HCV, HIV, B-19
parvovirus
No 60+ days 512 or
fewer
Baxter BioScience: United States, Austria,
Italy
HAV, HBV, HCV, HIV-1, B-19 parvovirus HAV, HBV, HCV, HIV-1/2,
B-19 parvovirus
No 60+ days 512 or
fewer
Talecris: United States HBV, HCV, HIV-1, B-19 parvovirus HBV, HCV, HIV-1, B-19
parvovirus
No 60+ days 96 or 480
Grifols: United States, Spain, Czech Republic,
Slovakia
HAV, HBV, HCV, HIV, B-19 parvovirus HBV, HCV, HIV, B-19
parvovirus
60+ days 512 or
fewer
Bio Products Laboratory, UK HAV, HBV, HCV, HIV-1/2, B-19 parvovirus HCV 60 days 512 or
fewer
Biotest: Germany HAV, HBV, HCV, HIV-1/2, B-19 parvovirus HBV, HCV, HIV No 60 days 960
Intersero, Germany HAV, HBV, HCV, HIV 1, B-19 parvovirus HBV, HCV, HIV 60+ days 960
German Red Cross BSO NSTOB HAV, HBV, HCV, HIV 1, B-19 parvovirus HCV 2 months 48
Octapharma: Sweden, Austria, Germany, USA HBV, B-19 parvovirus, HAV, HCV, HIV-1 HCV No 2 months 16-512
Finnish Red Cross BS: Finland HBV, HCV, HIV (individual)
HAV, B-19 parvovirus (mini-pool)
FRC BS does not make plasma
pools
1 or 96
Sanquin: The Netherlands HCV (6), HIV (6), HBV (6), B-19
parvovirus (480), HAV (480)
HBV, HCV, HIV, B-19
parvovirus
No 480 or 6
LFB: France 1: B-19 parvovirus 2: HAV, HCV HAV, HBV, HCV, HIV-1, B-19
parvovirus
80+ days 1: 300
2: 1000
Kedrion: Italy HBV, HCV, HIV 1, B-19 parvovirus (HAV if
required)
HCV 60+ days 480 or
fewer
National Bioproducts Institute: South Africa HAV, HCV, HIV, B-19 parvovirus HAV, HCV, HIV 1 and 216
CSL Biotherapies: Australia HCV, HIV HCV, HIV, B-19 parvovirus 480
Australian Red Cross Blood Service
Fractionated at CSL Biotherapies
HCV, HIV, B-19 parvovirus (optional) HCV, HIV, B-19 parvovirus 480/512
New Zealand Blood Service Fractionated at
CSL Biotherapies
HCV, HIV, B-19 parvovirus (optional) HCV, HIV, B-19 parvovirus 480/512
Hong Kong Red Cross BTS Fractionated at CSL
Biotherapies
HCV, HIV
Blood Services Group, Singapore Fractionated
at CSL Biotherapies
HCV, HIV HCV, HIV 480/512
National Blood Centre of Malaysia
Fractionated at CSL Biotherapies
HCV, HIV HCV, HIV 480/512
Taiwan Blood Services Foundation
Fractionated at CSL Biotherapies
HAV, HBV, HCV, HIV, B-19 parvovirus HCV, HIV (optional HBV,
HAV, B-19 parvovirus)
480/512
GreenCross: South Korea HAV, HCV HAV, HBV, HCV, HIV HAV, HBV, HCV, HIV 45 days b450
Japanese Red Cross: Japan HBV, HCV, HIV-1 HBV, HCV, HIV-1 HAV, HBV, HCV, HIV-1,
B-19 parvovirus
6 months 20
Kaketsuken: Japan 1: HBV, HCV, HIV-1 2: HAV, B-19
parvovirus
HAV, HBV, HCV, HIV-1, B-19
parvovirus
HAV, HBV, HCV, HIV-1,
B-19 parvovirus
6 months 1: 50 2: 500
Benesis: Japan HBV, HCV, HIV-1 HBV, HCV, HIV-1 HAV, HBV, HCV, HIV-1,
B-19 parvovirus
6 months 50
Shanghai RAAS Blood Products: China HBV, HCV, HIV-1 HBV, HCV, HIV-1 HBV, HCV, HIV-1 60+ days 48
HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV-1, human immunodeﬁciency virus-1; NAT, nucleic acid testing.
a The viruses which are screened for by the company or fractionator using NAT at mini-pool stage. Numbers in brackets indicate the mini-pool sizes for each NAT type (if applicable).
b The viruses which are screened for by the company or fractionator using NAT at manufacturing pool stage.
c The viruses which are screened for by the company or fractionator using NAT within the ﬁnal product (if any).
d Length of time that plasma is retained between donation and processing stages for donor information gathering.
e Amini-pool is a pool of donor samples, formedby directly pooling samples from individual donors or by pooling of samples from subpools. The numbers in the table indicate the number
of samples present in the pool [187].
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Patients with bleeding disorders should be vaccinated against
HAV and HBV. European studies have reported that universal HBV
vaccination of blood donors could be cost-effective as this measure
would reduce the risk of HBV transmission in general and might
even remove the necessity for general HBV NAT testing; however,
this would not reduce the risk posed by HBV escape variants (as
described earlier) [71,72].
5.3. Puriﬁcation and inactivation techniques
Blood/plasma-derived products typically undergo various proce-
dures designed to reduce the pathogen level, although these proce-
dures are not effective against all pathogens. Plasma donations
undergo quarantine (approximately 4–6 months) prior to fraction-
ation and when the donor is again screened negative FFP can thenbe subjected to chromatographic fractionation, solvent-detergent
treatment, nanoﬁltration and/or heat inactivation [73,74]. Prolonga-
tion of product storage time can be effective in reducing the infectiv-
ity of temperature-sensitive pathogens (such as T. pallidum).
Production of recombinant products also follows strict protocols to
remove and inactivate any viruses that might be present, even
though the risk of viral presence is minimal.
Although current puriﬁcation/inactivation techniques (such as
solvent-detergent treatment, nanoﬁltration and heat activation) do re-
duce the risk of pathogen transmission, they are not always sufﬁcient
to render blood/plasma-derived products safe [75]. Small non-
enveloped viruses (e.g. HAV, B19 and picornavirus) are often highly re-
sistant to inactivation procedures and may still be infectious in some
plasma-derived concentrates [75,76].
The presence of prions is also a concern. Attempts to remove prions
from plasma-derived products have involved several techniques, in-
cluding ion-exchange chromatography and nanoﬁltration [77,78].
Table 5
Approximate residual risk of HBV, HCV, HIV and HEV TTI in selected countries.
Virus Country Residual risk, or prevalence in blood
donations (dependent on testing) per
100,000
Reference
HBV Congo-Kinshasa 390 [188]
Brazil 289 [189]
USA 5.9–7.5 [58]
England/North Wales b3.7 [190]
Australia 2 [191]
Germany 0.4 [192]
Portugal 0.2 [193]
HCV Brazil 191 [189]
Germany 0.9 [192]
Portugal 0.03 [193]
HIV Congo-Kinshasa 22 [188]
Germany 0.9–2.4 [21,192]
HEV Germany 81 [42]
Netherlands 57 [42]
England 35 [50]
Scotland 6.9 [194]
Portugal 0.6 [193]
USA b2 [195]
HBV, hepatitis B virus; HCV, hepatitis C virus; HIV-1, human immunodeﬁciency virus-1;
TTI, transfusion-transmitted infection.
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exogenous “spikes” derived from prion-infected brain homogenates to
measure prion clearance, which may result in an overestimation of the
amount of prion removal, and the methods used for the estimation of
the reduction in prion load, which ideally should involve bioassay to
measure infectivity [79]. Further developments in this ﬁeld are required
to address these issues.
A recently proposed approach for the inactivation of infectious
agents in blood is whole-blood treatment with ultraviolet (UV)
light in combination with a photosensitiser such as riboﬂavin or
amotosalen [80,81]. The main disadvantage of this approach is that
UV treatment has been linked to the formation of neoantigens,
which may be generated via modiﬁcation of the surface antigens of
platelets. The presence of neoantigens may provoke a recipient
immune response during transfusion of UV-treated platelets, caus-
ing them to be rapidly cleared from the circulation [81]. While this
approach to pathogen inactivation is currently used for platelets
and is effective, it needs further reﬁnement for the inactivation of
whole blood [81,82].5.4. Product choice
The WFH strongly recommends the use of plasma-derived or
recombinant products in preference to cryoprecipitate or fresh fro-
zen plasma, as the infectious load of any infectious human pathogen
is lower in plasma-derived products than in cryoprecipitate, and
even lower in recombinant products [2].In some European countries,
recombinant products have almost completely replaced plasma-
derived products [12]. The use of recombinant products, which
have been manufactured and formulated with minimal addition of
human/animal-derived materials, greatly reduces the risk of recipi-
ent exposure to plasma-derived infectious agents and after they
have undergone virus removal/inactivation processes, recombinant
products can be considered to be as safe as currently possible [83].
Despite these beneﬁts, the use of recombinant products may be lim-
ited by higher costs and perceived problems of inhibitor formation
[83]. For indications where no recombinant factor concentrates are
available, the use of inactivated plasma-derived concentrates is
safer than fresh frozen plasma and will reduce the risk of other ad-
verse effects such as hypervolemia, transfusion-related lung injury
(TRALI) and hypersensitivity [84].6. Barriers to a minimal risk approach
Aminimal risk approachwould ensure that patients receive effective
treatmentwith the lowest possible risk, but this is difﬁcult to achieve in
practical terms. Regulatory needs in different European countries are
usually based on recommendations from the medical community, so
in order to achieve minimal risk, it would be ideal for these regulations
to be standardised and mandatory in all countries. Directives issued
by the European Union Commission describe the regulatory require-
ments for the safety of whole blood and plasma, stating that “all pre-
cautionary measures during their collection, processing, distribution
and use need to be taken making appropriate use of scientiﬁc prog-
ress in the detection and inactivation and elimination of transfusion
transmissible pathogenic agents” [85]. However, the relative safety
of different screening tests, products and processing methods is not
discussed and so individual countries may adopt different ap-
proaches towards minimising risk. Although recombinant products
are associated with the highest level of pathogen safety, higher
costs for development and production may make them too expen-
sive for some healthcare systems [86]. Inhibitor formation also re-
mains an important element of concern with both plasma-derived
and recombinant products, particularly with regard to FVIII in
haemophilia A [87]. The risk of inhibitor formation was shown to
be greater with recombinant versus plasma-derived factor VIII con-
centrates in some cohort studies [88], but similar in others [89].
In light of these considerations (availability, adverse reactions and
cost), it appears that the issue of pathogen safety of blood/plasma-
derived products is highly important but may not be the limiting factor
with respect to overall patient safety. The beneﬁts of treatment with a
hypothetically ‘unsafe’ plasma-derived product may outweigh the risk
of a negative outcome (e.g. bleeding, inhibitor formation), although
we suggest that itmay be clinically simpler to dealwith inhibitor forma-
tion than to combat an infection from an unknown or untreatable
pathogen.7. Current knowledge gaps and areas of unmet need
There are still signiﬁcant knowledge gaps and areas of unmet
need with respect to the pathogen safety of blood/plasma-derived
and recombinant products. The incidence of HBV, HCV and HIV TTI
has fallen to near or below 1 per million transfused units in the
industrialised world, indicating that current donor selection and
blood screening strategies have had a positive impact on blood safety
[14]. However, it is clear that screening both donors and donated
blood cannot exclude all known pathogens or eliminate all risks
from emerging pathogens [63,90]. Historical precedent indicates
that the blood supply is always vulnerable to contamination by hith-
erto non-prevalent/unknown pathogens, and that this risk cannot be
accurately gauged [91]. As we identify new infectious agents of con-
cern and develop new tests for their detection, it will also be neces-
sary to clearly deﬁne the infectious dose range for each agent and
use appropriately sensitive tests for their identiﬁcation. For example,
in suspected cases of vCJD infection, considerable challenges remain
in the development of screening and conﬁrmatory tests that have
sufﬁcient sensitivity and speciﬁcity to be of use in both a clinical set-
ting and within blood banks [92].
Surveillance of peoplewith haemophilia is required tomonitor path-
ogen safety issues related to blood and plasma products. The European
Haemophilia Safety Surveillance system (EUHASS), which began in
2008, is a pharmacovigilance programme which spans 25 European
countries and is designed to detect, monitor and investigate adverse
drug reactions. Reports of adverse events (such as acute/allergic events,
TTIs and inhibitors) are submitted to EUHASS by participating centres
and cumulative patient and clotting factor data are recorded annually
[93].
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in addition to a task force, should be developed to respond quickly to
any emerging infections. Such a plan should include long-term storage
of samples fromproduced batches (for retesting in the case of outbreaks
with known or recently emerged infectious agents) and guidance on re-
sponsibility for developing/performing tests for emerging pathogens
(industry vs. regulatory agencies). Guidance on approaching patients
who have potentially been infected and surveillance strategies for pa-
tients at high risk would also be beneﬁcial.
8. Conclusions
The majority of evidence indicates that the concept of clinical safety
of blood/plasma derivatives does not necessarily correspond to the con-
cept of pathogen safety; blood can only be classed as microbially safe in
reference to the infectious agents that are known and have been
screened for. Establishingwhether the presence of undetectedmicrobes
in the blood is clinically relevantwill require further long-term, detailed
studies. It should also be noted that even though the risk of transmission
of key detectable viruses (such as HIV, HBV and HCV) via transfusion
has fallen signiﬁcantly, transmission does still occur.
In general, balancing safety, efﬁcacy and practicalities is a difﬁcult
goal to achieve — patient safety is typically the key driver, but striv-
ing for near-complete safety at the expense of the patient's health or
quality of life may not be the best course of action for patients or cli-
nicians. The lack of a cohesive international strategy for blood dona-
tion and screening is a pressing concern that needs to be addressed.
Furthermore, a formal coordinated continuous risk-assessment and
management action plan needs to be developed to deal with the con-
stant potential risk of emerging infections. Establishing an interna-
tional registry (or harmonising data collection in National
Registries) and dedicated task force may help to identify newly
emerging pathogens more rapidly than in the past and to further im-
prove pathogen safety of blood/plasma-derived products and the
blood supply in general.
Practice points
• The use of blood/plasma-derived products for the treatment of bleed-
ing disorders carries a risk of pathogen transmission.
• Blood donations are screened for key pathogens such as HBV, HCV,
HIV and the causative agent of syphilis, but other screening tests
should be conducted as required according to geographical location
and patient risk factors.
• Screening tests for pathogens may lack sensitivity/speciﬁcity and so
false negatives may occur, resulting in a residual pathogen risk to
patients.
• In terms of pathogen safety, recombinant products (products which
have hadminimal exposure to blood/plasma-derived proteins) are con-
sidered to pose the lowest level of risk to patients.
Research agenda
• Regional and international rates of transfusion-transmitted infection
for key pathogens and emerging pathogens
• Safety and efﬁcacy of blood/plasma-derived products and recombi-
nant products for treatment of bleeding disorders.
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